AKTS
Aktis Oncology·NASDAQ
--
--(--)
--
--(--)
3.94 / 10
Netural
One analyst rates AKTS a Strong Buy, but with zero historical win rate. Fund‑flow score is 7.88, showing overall positive inflows, especially from block, medium and large investors, while small and extra‑large flows are negative. Liquidity is supportive but sentiment remains neutral.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-09
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for AKTS?
- AKTS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.94/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
